FDA trial shows sustained effect for Ozurdex on diabetic
The dexamethasone intraocular implant OZURDEX® (Allergan)
can bring about significant and visual improvement in patients
with diabetic macular oedema, with generally only transient
increases in IOP but with a high incidence of cataract in
phakic patients, said EURETINA president ,Francesco
Bandello MD, told attendees at an EURETINA free paper
session
He reported the pooled results of two FDA studies conducted
by the MEAD study group involving a total of 1048 patients
with diabetic macular oedema. The patients were randomised
into three groups to receive Ozurdex at a dosage of 0.7 mg or
0.35 mg , or sham treatment, with repeated injections when
indicated at intervals no shorter than six months.
Latest Articles
Simulators Benefit Surgeons and Patients
Helping young surgeons build confidence and expertise.
How Many Surgeries Equal Surgical Proficiency?
Internet, labs, simulators, and assisting surgery all contribute.
Improving Clinical Management for nAMD and DME
Global survey data identify barriers and opportunities.
Are Postoperative Topical Antibiotic Drops Still Needed?
Cataract surgeons debate the benefits of intracameral cefuroxime prophylaxis.
Emerging Technology for Detecting Subclinical Keratoconus
Brillouin microscopy shows promise in clinical studies.
Knowing Iris Repair: Modified Trifold Technique
Part eight of our series covers the modified trifold technique for large iris defects.
It’s All About Biomechanics!
Increasing the pool of patients eligible for refractive surgery.
Uncovering More Safe and Quick Options
Different strategies, such as PresbyLASIK, can offer presbyopes good outcomes.
Topography-Guided PRK for Keratoconus
Improving visual acuity in patients with keratoconus.
Defining AMD Treatment Protocol
Treatments trending to fewer injections for better results.